42,232 results match your criteria Lymphoma Non-Hodgkin


Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.

JAMA Netw Open 2019 Feb 1;2(2):e190035. Epub 2019 Feb 1.

Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora.

Importance: Axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, represents a new and potentially curative treatment option for B-cell lymphoma. It is expected to have long-term survival benefits; however, long-term survival data are limited.

Objective: To estimate the long-term survival and cost-effectiveness of axicabtagene ciloleucel for treatment of relapsed or refractory B-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2019.0035DOI Listing
February 2019

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor T-cell therapy.

Expert Rev Hematol 2019 Feb 22. Epub 2019 Feb 22.

a Division of Medical Oncology, Department of Internal Medicine , University of Washington School of Medicine , Seattle , WA , USA.

Introduction: Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated remarkable anti-tumor activity in B-cell malignancies and is under investigation in other hematologic malignancies and solid tumors. While highly efficacious, post-infusion T cell activity often results in massive cytokine release precipitating cytokine release syndrome (CRS), the signature toxicity of CAR T cells. This toxicity is characterized by systemic immune activation resulting in fever, hypotension, respiratory insufficiency and capillary leak. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1585238DOI Listing
February 2019

Prognostic impact of mutation, proliferative index and cell origin in diffuse large B cell lymphoma.

Hematol Transfus Cell Ther 2019 Jan-Mar;41(1):50-56. Epub 2018 Oct 24.

Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil.

Background: Diffuse large B-cell lymphoma, among non-Hodgkin lymphomas, is one of the most frequent subtypes. Clinical laboratory data and post-treatment outcomes are scarce in the Brazilian population.

Objective: The main objective of this retrospective study was to assess the impact of tumor markers, including the Myeloid differentiation primary response 88 (MYD88) mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.htct.2018.05.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371411PMC
October 2018

Palliative splenic irradiation for symptomatic splenomegaly in non-Hodgkin lymphoma.

Ecancermedicalscience 2018 13;12:887. Epub 2018 Dec 13.

Department of Radiation Oncology, Hospital de Braga, Braga, Portugal.

Introduction And Aims: Splenic marginal zone lymphoma, an uncommon subtype of non-Hodgkin lymphoma (NHL), is usually present with symptomatic splenomegaly. Although splenectomy has long been considered the first-line therapy in symptomatic or cytopenic patients, it can lead to significant morbidity and mortality. Splenic irradiation is an option for patients who have a poor response to systemic therapy and/or are not surgical candidates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2018.887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351061PMC
December 2018

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

University of Virginia School of Medicine, Charlottesville, Virginia, USA.

CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However many patients acquire resistance, demonstrating the need for new and improved drugs. We previously demonstrated that the natural process of antibody hexamer formation on targeted cells allows for optimal induction of complement-dependent cytotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.207266DOI Listing
February 2019

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.

J Immunother Cancer 2019 Feb 21;7(1):51. Epub 2019 Feb 21.

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Background: The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved outcomes in MCL patients who were predicted not to respond to conventional therapy, but it is unlikely to be curative. Chimeric antigen receptor-modified T (CAR T) cells exhibit very effective function in elimination of relapsed/refractory B-cell lymphoid malignancies, we investigated their use in a patient with relapsed MCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0529-9DOI Listing
February 2019

The impact of early diagnosis on the prognosis of extranodal NK/T-cell lymphoma with massive lung involvement: a case report.

BMC Pulm Med 2019 Feb 21;19(1):48. Epub 2019 Feb 21.

Department of Hematology, Kobe City Medical Center General Hospital, 2-1-1, Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan.

Background: Pulmonary non-Hodgkin lymphoma (NHL) is rare. The most frequent subtype of pulmonary NHL is low-grade B-cell lymphoma, such as lymphoma of mucosa-associated lymphoma tissue. Extranodal natural killer cell/T-cell lymphoma, nasal type (ENKL) is characterized by predominant extranodal involvement and association with Epstein-Barr virus (EBV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12890-019-0815-9DOI Listing
February 2019

Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on F-FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphoma.

Cancer Med 2019 Feb 20. Epub 2019 Feb 20.

Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphoma. High total metabolic tumor volume (TMTV) calculated using F-FDG PET/CT images at diagnosis predicts poor prognosis of patients with DLBCL. However, high cost and poor access to the imaging facilities hamper wider use of F-FDG PET/CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1973DOI Listing
February 2019

Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.

Cell Oncol (Dordr) 2019 Feb 21. Epub 2019 Feb 21.

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.

Purpose: Increased glycolytic activity with accumulation of extracellular lactate is regarded as a hallmark of cancer. In lymphomas, FDG-PET has undeniable diagnostic and prognostic value, corroborating that these tumours are avid for glucose. However, the role of glycolytic metabolism-related molecules in lymphoma is not well known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-019-00426-2DOI Listing
February 2019

Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Aesthet Surg J 2019 Feb 21. Epub 2019 Feb 21.

Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.

Background: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon type of non-Hodgkin lymphoma occurring in the fluid or capsule adjacent to textured breast implants. Diagnosis of BIA-ALCL of symptomatic patients requires demonstration of large anaplastic cells with uniform expression of CD30 protein on immunohistochemistry.

Objective: The authors investigated a novel, rapid, office-based, and economic in-situ enzyme-linked immunosorbent assay (ELISA) for screening BIA-ALCL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/asj/sjy327DOI Listing
February 2019

Primary Vaginal Non-Hodgkin Lymphoma.

Cureus 2018 Dec 11;10(12):e3713. Epub 2018 Dec 11.

Internal Medicine, Universidad Nacional Mayor De San Marcos, Lima, PER.

Non-Hodgkin lymphoma (NHL) is a type of blood cancer and 25% of NHL patients present with a primary extranodal tumor. Primary NHL of the vagina is extremely rare with only a few cases reported. We present the case of a 79-year-old, grand multipara, Peruvian woman with an eleven-month history of symptoms of pelvic and vaginal pain and vaginal bleeding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3713DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373882PMC
December 2018

Lymphoma diagnostics: getting more from less.

Br J Haematol 2019 Feb 19. Epub 2019 Feb 19.

Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT, USA.

In the modern era, clinicians and pathologists increasingly make challenging diagnoses in patients with suspected lymphoma using minimal amounts of diagnostic material. The increase in utilization of minimally invasive procedures, such as fine needle aspiration or needle core biopsies, lead to challenges in our ability to make accurate histopathological assessments of disease, including the integration of new diagnostic and prognostic testing, with smaller amounts of material. The trend towards minimally invasive diagnostics is also often in conflicting interest with researchers seeking to study tissue specimens to better understand the biology and genetics of these diseases to move the field forward. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15788DOI Listing
February 2019

CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients.

Authors:
Edward A Copelan

Oncology (Williston Park) 2019 Feb 15;33(2). Epub 2019 Feb 15.

View Article

Download full-text PDF

Source
February 2019

The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells.

Blood 2019 Feb 19. Epub 2019 Feb 19.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have not been identified. We report multivariable analyses of factors impacting response and progression-free survival (PFS) in aggressive NHL patients treated with cyclophosphamide and fludarabine (Cy/Flu) lymphodepletion followed by 2x10 CD19 CAR-T cells/kg. The best overall response rate (ORR) was 51%, with 40% of patients achieving complete remission (CR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-887067DOI Listing
February 2019

New directions in treating peripheral T-cell lymphomas (ptcl): leveraging epigenetic modifiers alone and in combination.

Expert Rev Hematol 2019 Feb 20. Epub 2019 Feb 20.

a Center for Lymphoid Malignancies, Division of Hematology and Oncology, Department of Medicine , Columbia University Medical Center, College of Physicians and Surgeons , New York , N.Y. , USA.

Introduction: The peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of non-Hodgkin lymphomas originating from mature T- and NK-cells. They are aggressive diseases often resistant to chemotherapy. Areas Covered: The methodology of this review involves a literature search of data published on PubMed, abstracts from international conferences, and our own research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583102DOI Listing
February 2019

CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant.

J Cutan Pathol 2019 Feb 18. Epub 2019 Feb 18.

Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy.

Intravascular large B-cell lymphoma (IVLBCL) is one of the rarest B-cell non Hodgkin lymphomas (NHL), with an aggressive clinical behavior and a poor prognosis; in fact, its treatment is still an unmet clinical need, with a 3-year overall survival (OS) rate of 60-81%, and a central nervous system relapse rate of 25%. It usually presents as a widespread disease at diagnosis with multi-organ involvement. Previously considered as a diffuse large B-cell lymphoma variant, it now represents a different extranodal large B-cell lymphoma entity in the last WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13446DOI Listing
February 2019

Breast cancer in women living with HIV.

Eur Rev Med Pharmacol Sci 2019 Feb;23(3):1158-1164

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

With the introduction of HAART, the life expectancy of the patients infected with HIV almost approached that of the general population. The incidence of certain HIV-Associated cancers as Kaposi Sarcoma (KS) and Non-Hodgkin Lymphoma (NHL) decreased, while an increase in Non-AIDS-Defining cancers (NADCs) has been documented. HIV infection is a risk factor for numerous cancers in PLWH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_201902_17007DOI Listing
February 2019

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.

Methods Mol Biol 2019 ;1956:199-228

Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.

Minimal residual disease (MRD) diagnostics is of high clinical relevance in patients with indolent B-cell non-Hodgkin lymphomas (B-NHL) and serves as a surrogate parameter to evaluate treatment effectiveness and long-term prognosis. MRD diagnostics performed by real-time quantitative PCR (RQ-PCR) is still the gold standard and currently the most sensitive and the most broadly applied method in follicular lymphoma (FL) and mantle cell lymphoma (MCL). Alternatively, droplet digital PCR (ddPCR) can be used for MRD monitoring in multiple myeloma, mantle cell lymphoma, and follicular lymphoma with comparable sensitivity, accuracy, and reproducibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_9DOI Listing
January 2019

Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas.

Methods Mol Biol 2019 ;1956:35-60

Department of Laboratory Medicine, University of Washington Medical Center, Seattle, WA, USA.

Multiparametric flow cytometry is a powerful diagnostic tool that permits rapid assessment of cellular antigen expression to quickly provide immunophenotypic information suitable for disease classification. This chapter describes a general approach for the identification of abnormal lymphoid populations by flow cytometry, including B, T, NK, and Hodgkin lymphoma cells suitable for the clinical and research environment. Knowledge of the common patterns of antigen expression of normal lymphoid cells is critical to permit identification of abnormal populations at disease presentation and for minimal residual disease assessment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_2DOI Listing
January 2019

Intravascular large B-cell lymphoma: The Great Imitator.

Autops Case Rep 2018 Oct-Dec;8(4):e2018055. Epub 2018 Nov 30.

University of Vermont Medical Center, Department of Pathology and Laboratory Medicine. Burlington, Vermont, USA.

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of diffuse large B-cell lymphoma with an estimated incidence of less than one per million. Unlike other hematopoietic malignancies, lymphadenopathy and hepatosplenomegaly are uncommon, and patients typically present with nonspecific symptoms. IVLBCL presents a diagnostic challenge and patients are usually diagnosed late in the disease course, if at all, and the prognosis is poor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4322/acr.2018.055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360824PMC
November 2018

Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.

Leuk Lymphoma 2019 Feb 18:1-10. Epub 2019 Feb 18.

g Department of Medicine , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Korea.

Although targeted deep sequencing of cell-free DNA (cfDNA) was recently used to investigate tumor somatic mutations in particular subtypes of non-Hodgkin lymphomas (NHLs), the immense genetic heterogeneity across subtypes poses a hurdle to design a universal gene panel applicable for diverse subtypes of NHLs. We designed a panel targeting 66 genes associated with NHLs and performed targeted deep sequencing to analyze plasma cfDNA from patients with various subtypes of NHLs. Genetic profiling in plasma cfDNA using the method resulted in 88. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1573998DOI Listing
February 2019
1 Read

[Clinicopathological features and possible prognostic factors in parotid lymphomas].

Beijing Da Xue Xue Bao Yi Xue Ban 2019 Feb;51(1):35-42

Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.

Objective: To investigate the clinicopathological features and prognostic factors in lymphoma of parotid origin.

Methods: Clinicopathological data of the patients with parotid lymphoma who were initially diagnosed in Peking University Hospital of Stomatology from 2006 to 2016 were collected and analyzed retrospectively. The patients were followed-up for 5 to 149 months with a median period of 45 months, and the factors influencing the prognosis were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19723/j.issn.1671-167X.2019.01.007DOI Listing
February 2019

Prevalence of deaths in a cohort of girls and women with cryopreserved ovarian tissue.

Acta Obstet Gynecol Scand 2019 Feb 15. Epub 2019 Feb 15.

The Fertility Clinic, section 4071, University Hospital of Copenhagen Rigshospitalet, Copenhagen, Denmark.

Introduction: Ovarian tissue cryopreservation (OTC) is increasingly offered to women in need of fertility preservation. However, little is known about the risk of these women dying before they use the preserved material.

Material And Methods: From 1999 to 2016, 927 girls and women underwent OTC in our center, prior to receiving gonadotoxic treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.13576DOI Listing
February 2019
1 Read

The Roles of FDG PET-CT in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy Treating Patients with Non-Hodgkin Lymphoma.

Biol Blood Marrow Transplant 2019 Feb 12. Epub 2019 Feb 12.

PET-CT Center, the First Affiliated Hospital, Zhejiang University. Electronic address:

Background: CD19-targeting chimeric antigen receptor (CAR) T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), but has been associated with serious adverse effects such as cytokine release syndrome (CRS). It has been speculated that NHL baseline disease burden might affect clinical outcome and CRS, but such assumption has not been explored in detail. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as measured by FDG PET-CT, are quantitative indicators of baseline tumor burden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.008DOI Listing
February 2019
1 Read

Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.

Br J Haematol 2019 Feb 14. Epub 2019 Feb 14.

Celgene Corporation, Summit, NJ, USA.

Chemotherapy plus rituximab has been the mainstay of treatment for follicular lymphoma (FL) for two decades but is associated with immunosuppression and relapse. In phase 2 studies, lenalidomide combined with rituximab (R ) has shown clinical synergy in front-line and relapsed/refractory FL. Here, we show that lenalidomide reactivated dysfunctional T and Natural Killer (NK) cells ex vivo from FL patients by enhancing proliferative capacity and T-helper cell type 1 (Th1) cytokine release. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15797DOI Listing
February 2019
4 Reads

Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma.

Hepatol Commun 2019 Feb 28;3(2):220-226. Epub 2018 Dec 28.

Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD.

Nonalcoholic fatty liver disease is the most common liver disorder in the developed world. Although typically reflecting caloric overload, it can also be secondary to drug toxicity. We aimed to describe the incidence and risk factors for steatosis during chemotherapy for non-Hodgkin lymphoma (NHL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep4.1304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357828PMC
February 2019
1 Read

Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant.

J Am Soc Nephrol 2019 Feb 14. Epub 2019 Feb 14.

School of Public Health, University of Sydney, Sydney, Australia.

Patients with ESRD have a substantially increased cancer risk, but few studies have examined the patterns of cancer mortality along a patient's journey from dialysis to transplantation.

Methods: We identified all Australian patients on dialysis and patients with transplants from 1980 to 2014 from the Australia and New Zealand Dialysis and Transplant Registry. Using standardized mortality ratios (SMRs), we compared cancer mortality among patients on dialysis and patients with transplants versus the general population (overall and by age, sex, year, and site); we also performed a subgroup analysis excluding patients with preexisting cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1681/ASN.2018090906DOI Listing
February 2019
2 Reads
9.343 Impact Factor

Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma.

Biol Blood Marrow Transplant 2019 Feb 11. Epub 2019 Feb 11.

Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX. Electronic address:

We analyzed 186 patients with lymphoma who received allogeneic stem cell transplant (ASCT) with fludarabine-melphalan (FM) conditioning and different donors [25 haploidentical (HD), 98 matched unrelated (MUD), and 63 matched related (MRD)] at our institution between 09/2009-01/2018. Patients received fludarabine 160 mg/m (40 mg/m/day x 4 days) in combination with one dose of melphalan 140 mg/m (FM140) or 100 mg/m2 (FM100). Engraftment was similar between the 3 groups (92%, 89%, and 98%, respectively; p=0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.002DOI Listing
February 2019
2 Reads

Effects of live music during chemotherapy in lymphoma patients: a randomized, controlled, multi-center trial.

Support Care Cancer 2019 Feb 14. Epub 2019 Feb 14.

Department of Endocrinology, Hospital of Southwest Jutland, Esbjerg, Jutland, Denmark.

Purpose: Chemotherapy is associated with both somatic and psychological side effects. Music might ease these problems. Several randomized controlled trials have investigated the effect of music, but the results are inconclusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04666-8DOI Listing
February 2019
2 Reads

A Rare Case of Bilateral Proptosis.

Eur J Case Rep Intern Med 2018 28;5(11):000966. Epub 2018 Nov 28.

Medicine IV Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal.

A 65-year-old man presented with a 2-year history of severe bilateral proptosis, palpable lymphadenopathy and moderate hepatosplenomegaly. A blood test was positive for hepatitis C infection. CT showed palpebral infiltrative lesions with regional progression through the temporal and masticatory spaces to the pharynx and hypopharynx causing almost complete airway obstruction. Read More

View Article

Download full-text PDF

Source
https://www.ejcrim.com/index.php/EJCRIM/article/view/966
Publisher Site
http://dx.doi.org/10.12890/2018_000966DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346810PMC
November 2018
4 Reads

Transcatheter Aortic Valve Replacement and Cardiac Resynchronization Therapy in Cancer-Related Cardiotoxicity.

J Cardiovasc Echogr 2018 Oct-Dec;28(4):233-235

Department of Cardiology, Monaldi Hospital, AORN dei Colli, Naples, Italy.

Cardiotoxicity related to antineoplastic agents is a rising and growing issue, therefore early recognition and prompt management can impact on the overall prognosis of cancer patients. We report the case of a 70-year-old woman without cardiovascular risk factors, with a medical history of non-Hodgkin lymphoma and chronic myeloid leukemia treated with chemotherapy and radiotherapy, who underwent transcatheter aortic valve replacement for severe aortic stenosis and cardiac resynchronization therapy for further development of complete left bundle branch block, with a significant improvement of her functional status and left ventricle systolic function in a long-term follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcecho.jcecho_46_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341852PMC
February 2019
1 Read

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

J Clin Oncol 2019 Feb 11:JCO1800915. Epub 2019 Feb 11.

19 University of Bologna, Bologna, Italy.

Purpose: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the basis of the activity of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-δ,-γ, in RR iNHL in a phase I study, the safety and efficacy of duvelisib monotherapy was evaluated in iNHL refractory to rituximab and either chemotherapy or radioimmunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00915DOI Listing
February 2019
1 Read

Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center.

Hematol Oncol 2019 Feb 11. Epub 2019 Feb 11.

Department of Hematology, Internal Medicine Division, Dr. José E. González University Hospital of the School of Medicine of the Universidad Autónoma de Nuevo León, Monterrey, México.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2579DOI Listing
February 2019
1 Read

Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.

Br J Haematol 2019 Feb 10. Epub 2019 Feb 10.

Blood Cancer Research Group, Mater Research, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia.

Primary mediastinal B-cell lymphoma (PMBCL) is a distinct disease closely related to classical nodular sclerosing Hodgkin lymphoma. Conventional diagnostic paradigms utilising clinical, morphological and immunophenotypical features can be challenging due to overlapping features with other B-cell lymphomas. Reliable diagnostic and prognostic biomarkers that are applicable to the conventional diagnostic laboratory are largely lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15778DOI Listing
February 2019
1 Read

Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment.

Br J Haematol 2019 Feb 10. Epub 2019 Feb 10.

University of Tennessee Health Science Center, Memphis, TN, USA.

In high-income countries, more than 90% of children with mature B-cell lymphomas are cured with frontline therapy. However, cure requires prompt and correct diagnosis, careful risk stratification, very intense chemotherapy and meticulous supportive care, together with logistical support for patients who live far from the cancer centre or face financial barriers to receiving care. In low- and middle-income countries (LMIC), cure rates range from 20% to 70% because of lack of diagnosis, misdiagnosis, abandonment of treatment, toxic death and excess relapse with reduced-intensity regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15785DOI Listing
February 2019
1 Read

[Clinicopathological Observation of Primary Renal Non-Hodgkin's Lymphoma--A Report of Two Cases].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):86-90

Department of Pathology, The Changzhou Municipal Second People's Hospital, Affiliated to Nanjing Medical University, Changzhou 213000, Jiangsu Province, China.

Objective: To investigate the clinicopathological and immunohistochemical features as well as diagnosis, differential diagnosis,treatment and prognosis of patients with primary renal non-hodgkin's lymphoma (PRNHL).

Methods: Clinical data of 2 patients with PRNHL from January 2013 to October 2017 were retrospectively analyzed.

Results: One of the two male patients PRNHL aged 51 years old, admitted to hospital for swelling and pain in the right waist, B-ultra sonic examination showed a very solid upper right renal space occupying lesion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.014DOI Listing
February 2019
2 Reads

Pediatric non-Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand.

Pediatr Int 2019 Jan;61(1):49-57

Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background: In the modern era of chemotherapy, the outcome of pediatric non-Hodgkin lymphoma (NHL) continues to improve internationally. Limited data such as information on epidemiology and survival, however, are available in Asian countries.

Methods: Children (≤15 years old) diagnosed with histologically proven NHL from 1998 to 2014 were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ped.13739DOI Listing
January 2019
1 Read

Relapsing Long-Lasting Garcin Syndrome Revealing Skull Base Diffuse B Cell Lymphoma: The Diagnosis through the "Hartel's Route".

J Neurol Surg B Skull Base 2019 Feb 8;80(1):105-108. Epub 2018 Jun 8.

Department of NESMOS (Neurosciences Mental Health and Sensory Organs), School of Medicine and Psychology, "Sant'Andrea" Hospital, "Sapienza" University of Rome, Rome, Italy.

The Garcin syndrome is a rare condition characterized by multiple unilateral cranial nerve palsy, without neither long-tract involvement nor intracranial hypertension. Non-Hodgkin lymphoma is a systemic malignant disease that localizes in a minority of cases in the central nervous system. We report a case of Garcin syndrome that revealed a diffuse large B cell lymphoma (DLBCL) located in the skull base and in the right kidney. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1657794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365233PMC
February 2019
1 Read

Diffuse Large B-Cell Lymphoma Relapsing in Leukaemic Phase Presenting as Acute Leukaemia.

Clin Med Insights Blood Disord 2019 15;12:1179545X18821160. Epub 2019 Jan 15.

Laboratory Oncology Unit, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, New Delhi, India.

Diffuse large B-cell lymphoma (DLBCL) accounts for 30% to 40% of the newly diagnosed adult non-Hodgkin lymphomas, but rarely presents in leukaemic phase. Here in, we report a case of DLBCL presenting in leukaemic phase and masquerading as acute leukaemia. A 28-year-old woman presented to our outpatient department with complaints of fever for 1 week. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1179545X18821160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343450PMC
January 2019
1 Read

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models.

Haematologica 2019 Feb 7. Epub 2019 Feb 7.

Università della Svizzera italiana, Institute of Oncology Research;

Antibody-drug conjugates (ADCs) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADCs targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, a novel ADC based on the SAR3419 anti-CD19 antibody linked via sulfo-SPDB to the potent DNA-alkylating agent DGN462. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.211011DOI Listing
February 2019
1 Read

Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma genetically unrelated to Burkitt lymphoma.

Haematologica 2019 Feb 7. Epub 2019 Feb 7.

Institut Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;

Burkitt-like lymphoma with 11q aberration is characterized by pathological features and gene expression profile resembling Burkitt lymphoma but lack MYC rearrangement and carries an 11q-arm aberration with proximal gains and telomeric losses. Whether these lymphomas are a distinct category or a particular variant of other recognized entities is controversial. To improve the understanding of Burkitt-like lymphoma with 11q aberration we have performed an analysis of copy number alterations and targeted sequencing of a large panel of B-cell lymphoma related genes in 11 cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.207928DOI Listing
February 2019
1 Read

Patterns of end-of-life hospital care for patients with non-Hodgkin lymphoma: exploring the landscape.

Leuk Lymphoma 2019 Feb 7:1-9. Epub 2019 Feb 7.

a Department of Medicine , University of Melbourne , Melbourne , Australia.

Rapid change, treatment responsiveness, and prognostication difficulties present challenges for palliative care integration for hematology patients. This Australian study aimed to document end-of-life hospital care for patients with non-Hodgkin lymphoma (NHL) to consider opportunities for palliative care integration. A retrospective population cohort design examining existing linked datasets of health service utilization and death registration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1564047DOI Listing
February 2019
1 Read

Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age.

Future Oncol 2019 Feb 7. Epub 2019 Feb 7.

Hematology, Azienda USL IRCCS Reggio Emilia, Italy.

The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin's lymphoma is identifying whether a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or too frail and therefore at risk of being undertreated. As cardiac comorbidities are an important contributor to both the health status and the selection of treatment, cardiovascular profiling and baseline risk stratification prior to treatment should be considered. Comprehensive geriatric assessment is an efficient means of identifying elderly patients with non-Hodgkin's lymphoma who may benefit from a curative treatment approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0019DOI Listing
February 2019
3 Reads

Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies.

Transfusion 2019 Feb 6. Epub 2019 Feb 6.

Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington.

Background: The clinical and procedural parameters that affect the optimal collection of lymphocytes for the production of chimeric antigen receptor (CAR) T cells remain undefined but are increasingly important, as commercial products are now available. We evaluated determinants of low lymphocyte collection efficiency (CE) and the rate of successful CAR T-cell manufacture in middle-aged and older adults with advanced B-cell malignancies.

Study Designs And Methods: Mononuclear cell collections using two apheresis platforms (COBE Spectra and Spectra Optia, Terumo BCT) from patients participating in a CD19-directed CAR T-cell therapy trial were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15178DOI Listing
February 2019
7 Reads

Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.

Br J Haematol 2019 Feb 6. Epub 2019 Feb 6.

Division of Paediatric Haemato-Oncology, Princess Maxima Centre for Paediatric Oncology, Utrecht, The Netherlands.

The 6th International Symposium on Childhood, Adolescent and Young Adult (CAYA) Non-Hodgkin Lymphoma (NHL) was held in Rotterdam, Netherlands, 26-29 September, 2018. This summary manuscript is a perspective on the presentations from the plenary scientific sessions, including wellness and survivorship, B-cell NHL, AYA lymphoma, translational NHL biology, lymphoma immunology, bone marrow transplantation and cell therapy, T/Natural Killer cell lymphoma, anaplastic large cell lymphoma, lymphoblastic lymphoma, novel lymphoma therapeutics and Hodgkin lymphoma. The symposium was attended by over 260 registrants from 42 different countries and included young, middle and senior investigators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15764DOI Listing
February 2019
1 Read

Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma.

Br J Haematol 2019 Feb 6. Epub 2019 Feb 6.

Pädiatrische Hämatologie und Onkologie, Justus-Liebig-Universität Gießen and Medical Faculty of the Martin-Luther University of Halle, Germany.

The epidemiology, outcome and targeted immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma were discussed during the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma September 26th-29th 2018 in Rotterdam, the Netherlands. This review summarizes some of those presentations, as well as other current and novel antibody therapy, immune check-point inhibitors, chimeric antigen receptor T cells, cancer vaccines and cytotoxic T lymphocyte therapy. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.15789
Publisher Site
http://dx.doi.org/10.1111/bjh.15789DOI Listing
February 2019
8 Reads

Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.

Hematol Oncol 2019 Feb 6. Epub 2019 Feb 6.

Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Chronic hepatitis C virus (HCV) infection is related with an increased risk of non-Hodgkin lymphomas (NHL). In indolent subtypes, regression of NHL was reported after HCV eradication with antiviral therapy (AT). In 2008 in Lombardy, a region of Northern Italy, the "Rete Ematologica Lombarda" (REL, Hematology Network of Lombardy-Lymphoma Workgroup) started a prospective multicenter observational cohort study on NHL associated with HCV infection, named "Registro Lombardo dei Linfomi HCV-positivi" ("Lombardy Registry of HCV-associated non-Hodgkin lymphomas"). Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2575
Publisher Site
http://dx.doi.org/10.1002/hon.2575DOI Listing
February 2019
6 Reads